The Global Fund has committed an additional Sh256 million ($2 million) to support Kenya’s rollout of the long-acting HIV prevention injection, Lenacapavir.
Starting Sunday, the state will cut its subsidies for the AIDS ​Drug Assistance Program (ADAP), and funds will only be available for people at or below 130% of the federal poverty level, a drop from ...
Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in ...
The emergency rule comes just one day before a planned hearing between the DOH and the AIDS Healthcare Foundation.
The Florida Department of Health has issued emergency rules that could sharply restrict access to HIV medications for ...
A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...
A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...
A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
US President's Emergency Plan for AIDS Relief (PEPFAR), the global HIV response has entered a second year of structural ...
Phase 3 trial results show BIC/LEN is noninferior to BIC/FTC/TAF for maintaining virologic suppression in adults with HIV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results